Showing 1–2 of 2 results for author: Elend, L
-
Earnings Prediction with Deep Learning
Authors:
Lars Elend,
Sebastian A. Tideman,
Kerstin Lopatta,
Oliver Kramer
Abstract:
In the financial sector, a reliable forecast the future financial performance of a company is of great importance for investors' investment decisions. In this paper we compare long-term short-term memory (LSTM) networks to temporal convolution network (TCNs) in the prediction of future earnings per share (EPS). The experimental analysis is based on quarterly financial reporting data and daily stoc…
▽ More
In the financial sector, a reliable forecast the future financial performance of a company is of great importance for investors' investment decisions. In this paper we compare long-term short-term memory (LSTM) networks to temporal convolution network (TCNs) in the prediction of future earnings per share (EPS). The experimental analysis is based on quarterly financial reporting data and daily stock market returns. For a broad sample of US firms, we find that both LSTMs outperform the naive persistent model with up to 30.0% more accurate predictions, while TCNs achieve and an improvement of 30.8%. Both types of networks are at least as accurate as analysts and exceed them by up to 12.2% (LSTM) and 13.2% (TCN).
△ Less
Submitted 12 October, 2020; v1 submitted 3 June, 2020;
originally announced June 2020.
-
Evolutionary Multi-Objective Design of SARS-CoV-2 Protease Inhibitor Candidates
Authors:
Tim Cofala,
Lars Elend,
Philip Mirbach,
Jonas Prellberg,
Thomas Teusch,
Oliver Kramer
Abstract:
Computational drug design based on artificial intelligence is an emerging research area. At the time of writing this paper, the world suffers from an outbreak of the coronavirus SARS-CoV-2. A promising way to stop the virus replication is via protease inhibition. We propose an evolutionary multi-objective algorithm (EMOA) to design potential protease inhibitors for SARS-CoV-2's main protease. Base…
▽ More
Computational drug design based on artificial intelligence is an emerging research area. At the time of writing this paper, the world suffers from an outbreak of the coronavirus SARS-CoV-2. A promising way to stop the virus replication is via protease inhibition. We propose an evolutionary multi-objective algorithm (EMOA) to design potential protease inhibitors for SARS-CoV-2's main protease. Based on the SELFIES representation the EMOA maximizes the binding of candidate ligands to the protein using the docking tool QuickVina 2, while at the same time taking into account further objectives like drug-likeliness or the fulfillment of filter constraints. The experimental part analyzes the evolutionary process and discusses the inhibitor candidates.
△ Less
Submitted 18 May, 2020; v1 submitted 6 May, 2020;
originally announced May 2020.
